Adsorbate Or Treating Agent Contains Nitrogen Patents (Class 424/78.12)
  • Patent number: 9918970
    Abstract: Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer.
    Type: Grant
    Filed: May 18, 2011
    Date of Patent: March 20, 2018
    Assignee: Astellas Pharma Inc.
    Inventors: Tatsunobu Yoshioka, Makoto Murai, Hiroaki Tasaki
  • Patent number: 9198864
    Abstract: A tablet comprising a coated drug-ion exchange resin complex composed of methylphenidate complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated methylphenidate-ion exchange resin complex is provided. The coated methylphenidate-ion exchange resin complex is in admixture with a polymer to form a matrix. Also provided is a tablet comprising a coated drug-ion exchange resin complex composed of dexmethylphenidate complexed with a pharmaceutically acceptable ion-exchange resin and an uncoated dexmethylphenidate-ion exchange resin complex is provided. The coated dexmethylphenidate-ion exchange resin complex is in admixture with a polymer to form a matrix.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: December 1, 2015
    Assignee: TRIS PHARMA, INC
    Inventors: Ketan Mehta, Yu-Hsing Tu
  • Patent number: 8802074
    Abstract: Polymeric compounds containing polymer backbones functionalized with ion-specific recognition elements and methods for the use of these compounds are described herein. The polymeric compounds may contain multiple types of ion-specific recognition elements depending on a specific application. The polymeric compounds can be used to remove ionic species from a solution, for example, in separations applications in which a single or multiple types of ionic species are desired to be removed from the solution.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: August 12, 2014
    Assignee: Board of Regents, The University of Texas System
    Inventors: Jonathan L. Sessler, Christopher W. Bielawski, Abdullah Aydogan, Daniel J. Coady
  • Patent number: 8545829
    Abstract: The present invention relates to pharmaceutical preparations for oral administration, comprising one or more active substances bound to an ion exchanger. In order to improve physical stability and acceptance, particularly in animals, a pseudoplastic gel-former thickener is included.
    Type: Grant
    Filed: May 19, 2003
    Date of Patent: October 1, 2013
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Dirk Mertin, Markus Edingloh, Gert Daube
  • Patent number: 8486428
    Abstract: The present invention includes methods and compositions for providing rechargeable aliphatic N-halamine polymers, monomers, copolymers additives and coatings. The rechargeable aliphatic N-halamine includes an aliphatic N-halamine compound exchangeable associated with one or more halides.
    Type: Grant
    Filed: March 27, 2006
    Date of Patent: July 16, 2013
    Assignee: Board of Regents, The University of Texas System
    Inventors: Yuyu Sun, Jie Luo
  • Patent number: 8409561
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
    Type: Grant
    Filed: August 16, 2010
    Date of Patent: April 2, 2013
    Assignee: Relypsa, Inc.
    Inventors: Dominique Charmot, Han-Ting Chang, Mingjun Liu, Futian Liu, Gerrit Klaerner
  • Patent number: 8404784
    Abstract: A novel process of manufacturing sevelamer carbonate from a polyallylamine carbonate or bicarbonate chloride salt. Process for manufacture of carbonate and/or bicarbonate salts of water insoluble polymers containing amino groups that are useful as anion binders in the gastrointestinal (GI) system. The process arranges the polyallylamine chain in a solution in such a way that the cross-linking reaction with epichlorohydrin can be controlled at a desired reaction rate.
    Type: Grant
    Filed: December 2, 2009
    Date of Patent: March 26, 2013
    Assignee: Navinta LLC
    Inventors: Christopher N. Jobdevairakkam, Hero Velladurai
  • Patent number: 8277834
    Abstract: The present invention is a method of manufacturing an eye lens material having a process in which a phosphorylcholine group-containing chemical compound represented by the following formula (1) is reacted and covalently bonded onto the surface of an eye lens material wherein a chemical compound having an end amino group is introduced to said eye lens material and then the chemical compound represented by the following formula (2) or (3) is introduced through said chemical compound having an end amino group. The object of the present invention is to provide a method of manufacturing a contact lens that prevents protein adsorption.
    Type: Grant
    Filed: May 18, 2005
    Date of Patent: October 2, 2012
    Assignees: Shiseido Company, Ltd.
    Inventors: Yukimitsu Suda, Kazuyuki Miyazawa, Kazuhiko Ishihara
  • Patent number: 8202962
    Abstract: Processes for making polyesters in a polyester production facility are disclosed, that include the steps of: forming a reaction medium comprising at least one monomer that includes terephthalic acid (TPA) and/or an ester derivative of TPA; subjecting at least a portion of the reaction medium to one or more chemical reactions in the polyester production facility to thereby produce the polyester; heating at least a portion of the reaction medium via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water; flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and heating one or more process fluid streams of the polyester production facility via indirect heat exchange with at least a portion of the lower-pressure steam, wherein the process fluid streams include any stream that is formed predominately of the reaction medium and/or the at lea
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: June 19, 2012
    Assignee: Grupo Petrotemex, S.A. de C.V.
    Inventors: Alan George Wonders, James Donald Simpson, Bruce Roger DeBruin
  • Patent number: 8198397
    Abstract: Integrated processes for making polyesters are disclosed, that include the steps of: (a) producing an aromatic polycarboxylic acid in a monomer production facility; (b) producing a polyester in a polyester production facility, wherein the producing of the polyester comprises the substeps of: (i) forming a polyester reaction medium comprising at least a portion of the aromatic polycarboxylic acid from the monomer production facility, (ii) subjecting at least a portion of the polyester reaction medium to one or more chemical reactions to thereby produce the polyester, (iii) heating the polyester reaction medium at one or more locations in the polyester production facility via indirect heat exchange with high-pressure steam, wherein the heating causes at least a portion of the high-pressure steam to condense and thereby provide pressurized condensed water, and (iv) flashing at least a portion of the pressurized condensed water to thereby produce lower-pressure steam; and (c) using at least a portion of the lower
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: June 12, 2012
    Assignee: Grupo Petrotemex, S.A. de C.V.
    Inventors: Alan George Wonders, James Donald Simpson, Bruce Roger DeBruin
  • Patent number: 8158117
    Abstract: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrochloride, hydrobromide, hydroacetate or hydroanionic form.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: April 17, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Katie Beth Williams, Katarzyna Barcyka
  • Patent number: 8114393
    Abstract: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrocitrate, hydrochloride, hydrobromide, hydroacetate or hydroanionic form.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: February 14, 2012
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Katarzyna M. Barycka, Lori Plum, Julia Zella, Margaret Clagett-Dame
  • Publication number: 20120027811
    Abstract: This invention relates to solid formulations for the oral delivery of live microbial cells which comprise dried viable cells and small amounts of a bile acid binding agent, for example, an anion exchange resin such as cholestyramine. The presence of bile acid binding agents in the formulation significantly increases the survival of the cells in the intestinal tract and facilitates delivery of the viable cells to the intestine.
    Type: Application
    Filed: January 11, 2010
    Publication date: February 2, 2012
    Applicants: Recipharmcobra Holdings Limited, Cambridge Enterprise Limited
    Inventors: Alexander Edwards, Nigel Slater
  • Patent number: 7854924
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: December 21, 2010
    Assignee: Relypsa, Inc.
    Inventors: Robert Alpern, Jerry Buysse, Han Ting Chang, Dominique Charmot, Michael James Cope, John Fordtran, Gerrit Klaerner, Eric Connor, Mingjun Liu, Futian Liu, Jun Shao
  • Publication number: 20100272671
    Abstract: Methods of treating diseases diabetes are disclosed. Methods of modulating elevated fructosamine levels, elevated HbA1c levels, impaired glucose tolerance, and impaired fasting glucose are also disclosed. In some embodiments, methods include co-administration of a biguanide and a bile acid sequestrant. Drug products including a biguanide and bile acid sequestrants in combination are also disclosed.
    Type: Application
    Filed: June 16, 2010
    Publication date: October 28, 2010
    Applicant: Daiichi Sankyo, Inc.
    Inventor: Michael R. Jones
  • Patent number: 7815898
    Abstract: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from saliva.
    Type: Grant
    Filed: November 29, 2005
    Date of Patent: October 19, 2010
    Assignee: CM&D Pharma Limited
    Inventor: Vincenzo Savica
  • Patent number: 7811600
    Abstract: Disclosed are implantable medical devices comprising nitric oxide (NO) donating polymers comprising polymer backbones having at least one cyclic amine disposed thereon. Methods are further disclosed for providing nitric oxide-donating polymers.
    Type: Grant
    Filed: March 8, 2007
    Date of Patent: October 12, 2010
    Assignee: Medtronic Vascular, Inc.
    Inventors: Peiwen Cheng, Mingfei Chen, Kishore Udipi
  • Publication number: 20100233116
    Abstract: The present invention provides heterocyclic derivatives hat modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: August 13, 2007
    Publication date: September 16, 2010
    Inventors: Natalie Dales, Julia Fonarev, Jianmin Fu, Rajender Kamboj, Vishnumurthy Kodumuru, Shifeng Liu, Natalia Pokrovskaia, Vandna Raina, Shaoyi Sun, Zaihui Zhang
  • Patent number: 7767768
    Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides polymeric and pharmaceutical compositions comprising crosslinked amine polymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of renal diseases and hyperphosphatemia.
    Type: Grant
    Filed: May 11, 2005
    Date of Patent: August 3, 2010
    Assignee: Ilypsa, Inc.
    Inventors: Han Ting Chang, Dominique Charmot, Eric Connor, Florence Roger
  • Publication number: 20100129309
    Abstract: A pharmaceutical composition for treating hyperphosphatemia can include polymers derived from multi-amine monomers and multifunctional monomers, where the multifunctional monomer includes more than one electrophilic group.
    Type: Application
    Filed: February 20, 2008
    Publication date: May 27, 2010
    Inventors: Pradeep K. Dhal, Stephen Randall Holmes-Farley, Chad C. Huval, Steven C. Polomoscanik
  • Patent number: 7718746
    Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: May 18, 2010
    Assignee: Ilypsa, Inc.
    Inventors: Eric Connor, Dominique Charmot, Han-Ting Chang, Florence Roger, Gerrit Klaerner, Son Hoai Nguyen, Jonathan Mills, Jerry M. Buysse, Angela Lee, Deidre Madsen, Jun Shao, Michael J. Cope, John Fordtran
  • Publication number: 20100055066
    Abstract: According to the present invention, an agent for prophylactic and/or therapeutic treatment of diabetes comprising a substance inhibiting activity of farnesoid X receptor as an active ingredient can be provided.
    Type: Application
    Filed: October 14, 2005
    Publication date: March 4, 2010
    Inventors: Kazuo Suzuki, Kaoru Sakai, Shinichi Ishii, Kanami Sugimoto, Johan Auwerx, Mitsuhiro Watanabe
  • Publication number: 20100021415
    Abstract: A cosmetic method for releasing an active principle in a controlled fashion to uninjured skin, as a function of the ion content in or on skin, by exchange with the ions, in order to provide at least one cosmetic benefit to the skin, the method includes applying onto skin a composition containing, in a cosmetically acceptable medium, at least one resinate including one organic ion-exchange resin and at least one ionizable cosmetic active principle bonded in noncovalent fashion to the resin.
    Type: Application
    Filed: March 14, 2008
    Publication date: January 28, 2010
    Applicant: CHANEL PARFUMS BEAUTE
    Inventors: Audrey Marjorie Casado-Chaudanson, Audrey Celine Marcelle Pastor
  • Patent number: 7608674
    Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.
    Type: Grant
    Filed: November 3, 2004
    Date of Patent: October 27, 2009
    Assignee: Ilypsa, Inc.
    Inventors: Eric Connor, Dominique Charmot, Han-Ting Chang, Florence Roger, Gerrit Klaerner, Son Hoai Nguyen, Jonathan Mills, Jerry M. Buysse, Angela Lee, Deidre Madsen, Jun Shao, Michael J. Cope, John Fordtran
  • Publication number: 20090004133
    Abstract: The present invention provides improved methods and compositions for therapeutically controlling and/or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrocitrate, hydrochloride, hydrobromide, hydroacetate or hydroanionic form.
    Type: Application
    Filed: October 12, 2007
    Publication date: January 1, 2009
    Inventors: Hector F. DeLuca, Katarzyna M. Barycka, Lori Plum, Julia Zella, Margaret Clagett-Dame
  • Patent number: 7459151
    Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: December 2, 2008
    Assignee: Genzyme Corporation
    Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III, George M. Whitesides
  • Patent number: 7459502
    Abstract: Anion-binding polymers are described. The anion-binding polymers in some cases are low swelling anion-binding polymers. In some cases, the anion-binding polymers have a pore volume distribution such that a fraction of the polymer is not available for non-interacting solutes above a certain percentage of the MW of the target ion for the polymer. In some cases, the anion-binding polymers are characterized by low ion-binding interference, where the interference is measured in, for example, a gastrointestinal simulant, relative to non-interfering buffer. Pharmaceutical composition, methods of use, and kits are also described.
    Type: Grant
    Filed: October 13, 2004
    Date of Patent: December 2, 2008
    Assignee: Ilypsa, Inc.
    Inventors: Eric Connor, Dominique Charmot, Han Ting Chang, Florence Roger, Gerrit Klearner, Son Hoai Nguyen
  • Publication number: 20080279808
    Abstract: The invention relates to novel compounds of general formula I wherein M represents hydrogen, or a metallic cation, preferably an alkaline metal, or alkaline-earth metal, and n is equal to 1, 2 or 3. The present invention also comprises compounds of general formula I in their equilibrium forms, including lactonic forms, their enantiomers in pure form, or in an enriched form in one of the optical isomers, racemic mixtures, diastereomers and solvates thereof. The present invention further relates to processes for the preparation of compounds of general formula I, to pharmaceutical compositions comprising compounds of general formula I as only active ingredient, or in association with other active ingredients. Another aspect of the invention is the use of compounds of general formula I for the treatment of dyslipidemia, associated, or not, to other metabolic disorders, such as glucose intolerance syndrome and type 1 or 2 diabetes mellitus, by means of isolated administration or combined with other substances.
    Type: Application
    Filed: November 15, 2006
    Publication date: November 13, 2008
    Inventors: Jorge Ruas Da Silva, Ana Maria Staack Reis Machado, Joaquim Alberto Barros Pereira, Joao Carlos Ramos Damil, Carlos Alberto Casimiro Caixado, Augusto Eugenio Pardal Filipe
  • Patent number: 7385012
    Abstract: The present invention provides polymeric and pharmaceutical compositions comprising a polymer that contains vicinal amine moieties, referred to as polyvicinalamine polymers. The polyvicinalamines can be copolymers or homopolymers. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of renal diseases, hyperphosphatemia, and the removal of bile acids, oxalates and iron from the gastrointestinal tract.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: June 10, 2008
    Assignee: Ilypsa, Inc.
    Inventors: Han Ting Chang, Dominique Charmot, Samir Zard
  • Patent number: 7220406
    Abstract: Amine polymers, particularly aliphatic amine polymers, are useful in the treatment and prevention of bone disease and in methods for promoting bone formation. Sevelemer, polyallylamine crosslinked with epichlorohydrin, which is sold under the tradename RenagelĀ®, is the preferred polymer used in the invention.
    Type: Grant
    Filed: October 16, 2003
    Date of Patent: May 22, 2007
    Assignee: Genzyme Corporation
    Inventor: Steven K. Burke
  • Patent number: 7147845
    Abstract: The present invention relates to novel antimicrobial silver ion complex resinates. More particularly, the present invention contemplates silver ion complex resinate compositions comprising a silver-thiosulfate ion complex loaded onto an organic anion exchange resin. These silver thiosulfate ion complex resinate compositions are able to release stable antimicrobial silver ion complexes when placed in a saline environment. These antimicrobial silver-ion complex resinates are useful in the treatment and prevention of infections and diseases.
    Type: Grant
    Filed: April 14, 2004
    Date of Patent: December 12, 2006
    Assignee: BioInterface Technologies, Inc.
    Inventor: Christopher C. Capelli
  • Patent number: 7087223
    Abstract: Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect of lowering blood phosphorus level and another effect of suppressing phosphorus excretion into the urine.
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: August 8, 2006
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Takeshi Goto, Kazuhisa Yoshitake, Hiroshi Sorimachi, Kazuteru Moriyama
  • Patent number: 7078050
    Abstract: A white cream bacteriostat and fungicide capable of serving as a vehicle for additional medicaments. Also disclosed is a method for blending the ingredients, some of which are not readily compatible with each other.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: July 18, 2006
    Inventor: Normajean Fusco
  • Patent number: 7067116
    Abstract: Physiologically acceptable films, including edible films, are disclosed. The films include a water soluble film-forming polymer, such as pullulan, and a taste masked pharmaceutically active agent, such as dextromethorphan. The taste masking agent is preferably a sulfonated polymer ion exchange resin comprising polystyrene cross-linked with divinylbenzene, such as AMBERLITE. Methods for producing the films are also disclosed.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: June 27, 2006
    Assignee: Warner-Lambert Company LLC
    Inventors: William S. Bess, Neema Kulkarni, Suhas H. Ambike, Michael P. Ramsay
  • Patent number: 7014846
    Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
    Type: Grant
    Filed: January 28, 2004
    Date of Patent: March 21, 2006
    Assignee: Genzyme Corporation
    Inventors: Stephen Randall Holmes-Farley, W. Harry Manderville, III, George M. Whitesides
  • Patent number: 6899868
    Abstract: The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I2 and polyiodide ion having a valence of ?1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.
    Type: Grant
    Filed: May 31, 2002
    Date of Patent: May 31, 2005
    Assignee: Triosyn Holding Inc.
    Inventor: Pierre Jean Messier
  • Patent number: 6858203
    Abstract: Phosphate-binding polymers are provided for removing phosphate from the gastrointestinal tract. The polymers are orally administered, and are useful for the treatment of hyperphosphatemia.
    Type: Grant
    Filed: December 17, 2002
    Date of Patent: February 22, 2005
    Assignee: Genzyme Corporation
    Inventors: Stephen Randall Holmes-Farley, W. Harry Mandeville, III, George M. Whitesides
  • Patent number: 6844372
    Abstract: An cross-linked anion exchange resin or a salt thereof obtained by reacting a polymer (A) having amino and/or imino groups in the total number of two or more per molecule with a compound (B) having two or more functional groups capable of reacting with amino and/or imino group contained in the polymer (A). The resin or salt has a water absorption ratio of 4.0 or lower.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: January 18, 2005
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Takeshi Goto, Kazuhisa Yoshitake, Kazuteru Moriyama, Shuichi Toriya, Tsutomu Yuasa, Hideyuki Nishibayashi
  • Publication number: 20040241135
    Abstract: The present invention relates to a resin comprising a bio-enhancer and an optional therapeutically active ingredient or precursor thereof loaded thereon. The bio-enhancer is ionizable or non-ionizable, and the resin may be a cation exchange resin or an anion exchange resin.
    Type: Application
    Filed: May 27, 2004
    Publication date: December 2, 2004
    Inventor: Lyn Hughes
  • Publication number: 20040228830
    Abstract: A multiparticulate milnacipran composition for oral administration has been developed. The formulation is made by complexing milnacipran with an ion-exchange resin in the form of small particles, typically less than 150 microns.
    Type: Application
    Filed: January 28, 2004
    Publication date: November 18, 2004
    Applicant: Collegium Pharmaceutical, Inc.
    Inventors: Jane Hirsh, Alison B. Fleming, Roman V. Rariy
  • Patent number: 6797259
    Abstract: The present invention relates to the delivery of muscle relaxants through an inhalation route. Specifically, it relates to aerosols containing a muscle relaxant that is used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of muscle relaxant. In a method aspect of the present invention, a muscle relaxant is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of a muscle relaxant, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: September 28, 2004
    Assignee: Alexza Molecular Delivery Corporation
    Inventors: Joshua D. Rabinowitz, Alejandro C. Zaffaroni
  • Publication number: 20040180034
    Abstract: The invention provides a pharmaceutical composition that includes a non-ionizable anthlemintic drug or derivative thereof loaded onto an anion exchange resin or a cation exchange resin. The non-ionizable anthlemintic is praziquantel, a praziquantel derivative, epsiprantel, or an epsiprantel derivative. The anthlemintic can also include Droncit, a derivative of Droncit, a precursor of Droncit, Drontal, a precursor of Drontal, a derivative of Drontal, Drontal Plus, a derivative of Drontal Plus, a precursor of Drontal Plus, a formulation comprising Praziquantel and Pyrantel Pamoate, and a formulation comprising Praziquantel, Pyrantel Pamoate and/or Febantel. In another variant, the invention includes a pharmaceutical composition including a basic anthlemintic drug loaded onto an anion exchange resin, or an acidic anthlemintic drug loaded onto a cation exchange resin, and a process for manufacturing the pharmaceutical composition.
    Type: Application
    Filed: February 20, 2004
    Publication date: September 16, 2004
    Inventors: Lyn Hughes, Witold Andrew Ziarno
  • Publication number: 20040105838
    Abstract: A pharmaceutical combination or composition containing a lipase inhibitor, preferably orlistat, and a bile acid sequestrant is useful for treating obesity.
    Type: Application
    Filed: November 20, 2003
    Publication date: June 3, 2004
    Inventors: Pierre Barbier, Paul Hadvary, Hans Lengsfeld
  • Publication number: 20040091450
    Abstract: This disclosure relates to compositions comprising an open-celled polymeric foam wherein the compositions are useful for sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body. The disclosure further relates to compositions comprising the open-celled polymeric foam wherein the compositions are useful for ameliorating side effects associated with the use of lipase inhibitors. In a preferred embodiment, this disclosure relates to compositions comprising polymeric foam materials made from high internal phase emulsions, where such foams are useful for sequestering lipophilic materials. Further disclosed are compositions comprising open-celled polymeric foams wherein the compositions are useful for the purpose of sequestering aqueous and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea.
    Type: Application
    Filed: October 31, 2003
    Publication date: May 13, 2004
    Applicant: The Procter & Gamble Company
    Inventors: Bryn Hird, Ronald James Jandacek
  • Patent number: 6726905
    Abstract: The present invention relates to a method for lowering the serum phosphate level of a patient. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer characterized by a diallylamine monomer or repeat unit. The amino nitrogen atom of the diallylamine repeat unit can be substituted by one or two substituents independently selected from among substituted and unsubstituted, normal, branched and cyclic alkyl groups, and aryl groups. When the diallylamine repeat unit comprises an ammonium or quaternary ammonium group, the monomer will further comprise a suitable anion, such as a conjugate base of a pharmaceutically acceptable acid.
    Type: Grant
    Filed: November 5, 1997
    Date of Patent: April 27, 2004
    Assignee: Genzyme Corporation
    Inventors: W. Harry Mandeville, III, Stephen Randall Holmes-Farley
  • Patent number: 6702997
    Abstract: The present invention relates to an albuterol inhalation solution, system, kit and method for relieving bronchospasm in children suffering from asthma. In one alternative embodiment, the solution of the present invention is a sterile, premixed, premeasured single unit dose of albuterol for asthmatic patients 2 to 12 years of age. The present solution may be free of anti-microbial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 0.63 mg or about 1.25 mg albuterol.
    Type: Grant
    Filed: December 28, 2001
    Date of Patent: March 9, 2004
    Assignee: Dey, L.P.
    Inventors: Imtiaz Chaudry, Partha Banerjee
  • Patent number: 6692732
    Abstract: A method for treating pathogenic toxins in a mammal, such as a human, comprising treating the mammal with a therapeutically effective amount of a polymer comprising a cationic group attached to the polymer backbone. The polymer can be a homopolymer or a copolymer. In one embodiment, the polymer is a copolymer comprising a monomer having a pendant ammonium group and a hydrophobic monomer.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: February 17, 2004
    Assignee: Genzyme Corporation
    Inventors: Richard Fitzpatrick, Chad Cori Huval, Caroline Isabelle Bacon Kurtz, W. Harry Mandeville, III, Thomas X. Neenan
  • Patent number: 6680050
    Abstract: The present invention relates to iodine demand disinfectants. It relates in particular to a process for preparing a polyiodide-resin for use as an iodine demand disinfectant wherein a porous strong base anion exchange resin in a salt form, is contacted with a material capable of donating a member absorbable by the resin so as to convert the resin to the polyiodide-resin. The adsorbable member is selected from the group comprising I2 and polyiodide ion having a valence of −1. The process is characterized in that conversion of the anion exchange resin to the polyiodide-resin is effected at elevated temperature and elevated pressure, the elevated temperature being 100 degrees C. or higher, the elevated pressure being greater than atmospheric pressure. The present invention also relates to disinfectant substance comprising an iodine (impregnated) resin as produced by the above process.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: January 20, 2004
    Assignee: Triosyn Holdings, Inc.
    Inventor: Pierre Jean Messier
  • Patent number: 6673338
    Abstract: The invention provides NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates, in which the N2O2− functional group is bonded to a carbon atom. The invention also provides compositions comprising such diazeniumdiolate compounds, and methods of using such compounds and compositions. The invention further provides a method of preparing NO— or NO−-releasing imidate, thioimidate, and amide diazeniumdiolates.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: January 6, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ernst V. Arnold, Larry K. Keefer, Joseph A. Hrabie
  • Publication number: 20030215395
    Abstract: The present invention provides a controllably degradable cationic polymer for delivery of biomolecules (nucleic acids, peptides, etc.), drugs, molecules used in medical imaging applications, sensitizing agents used in cancer treatments, and molecules used in tissue engineering. The present invention also provides a method for synthesizing the polymer according to the present invention.
    Type: Application
    Filed: October 11, 2002
    Publication date: November 20, 2003
    Inventors: Lei Yu, Fusheng Du, Shouping Ji, Kenji Matsumoto